22/04/2026 (Agence Europe) – The European Commission has authorised the first combined vaccine against Covid-19 and seasonal flu for people aged 50 and over, it announced on Wednesday 22 April. The decision has been published in the Union Register of medicinal products. The vaccine, called mCombriax, is based on messenger RNA (mRNA) technology. It aims to provide simultaneous protection against the SARS-CoV-2 virus and three seasonal influenza strains. Severe forms of Covid-19 and influenza mainly affect the elderly and immunocompromised. Co-infection with the two viruses can lead to more severe complications. mCombriax works by training the immune system to recognise the targeted viral proteins. It covers influenza strains type A-H1N1, type A-H3N2 and type B Victoria lineage. European authorisation is based on a positive scientific assessment (https://aeur.eu/f/ln3 ). This was issued by the European Medicines Agency (EMA), then validated by the European Commission. (LC)